GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BLIS Technologies Ltd (NZSE:BLT) » Definitions » Debt-to-EBITDA

BLIS Technologies (NZSE:BLT) Debt-to-EBITDA : 0.12 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is BLIS Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BLIS Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.18 Mil. BLIS Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NZ$0.21 Mil. BLIS Technologies's annualized EBITDA for the quarter that ended in Mar. 2024 was NZ$3.29 Mil. BLIS Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BLIS Technologies's Debt-to-EBITDA or its related term are showing as below:

NZSE:BLT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.83   Med: -0.07   Max: 2.08
Current: 2.08

During the past 13 years, the highest Debt-to-EBITDA Ratio of BLIS Technologies was 2.08. The lowest was -0.83. And the median was -0.07.

NZSE:BLT's Debt-to-EBITDA is ranked worse than
57.76% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs NZSE:BLT: 2.08

BLIS Technologies Debt-to-EBITDA Historical Data

The historical data trend for BLIS Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BLIS Technologies Debt-to-EBITDA Chart

BLIS Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.59 -0.37 -0.83 0.31

BLIS Technologies Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.69 -0.23 0.49 -0.65 0.12

Competitive Comparison of BLIS Technologies's Debt-to-EBITDA

For the Biotechnology subindustry, BLIS Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BLIS Technologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BLIS Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BLIS Technologies's Debt-to-EBITDA falls into.



BLIS Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BLIS Technologies's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.177 + 0.212) / 1.255
=0.31

BLIS Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.177 + 0.212) / 3.288
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2024) EBITDA data.


BLIS Technologies  (NZSE:BLT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BLIS Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BLIS Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BLIS Technologies (NZSE:BLT) Business Description

Traded in Other Exchanges
N/A
Address
442 Moray Place, Ground Floor, Dunedin, OTA, NZL, 9016
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets two strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 both of which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).

BLIS Technologies (NZSE:BLT) Headlines

From GuruFocus

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Olstein Strategic Opportunities Fund 2014 Investor Letter

By Canadian Value Canadian Value 04-01-2015

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012

John Rogers Comments on Blount Intl Inc.

By Holly LaFon Holly LaFon 01-22-2016